Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Purchases 25,000 Shares

Lipocine Inc. (NASDAQ:LPCN) CEO Mahesh Patel acquired 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was acquired at an average cost of $2.02 per share, with a total value of $50,500.00. Following the completion of the acquisition, the chief executive officer directly owned 135,679 shares in the company, valued at approximately $274,071.58. This represents a 22.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Lipocine Price Performance

Shares of Lipocine stock opened at $2.05 on Friday. Lipocine Inc. has a 1-year low of $1.81 and a 1-year high of $12.37. The business’s fifty day moving average price is $8.45 and its two-hundred day moving average price is $5.75. The company has a market capitalization of $14.97 million, a P/E ratio of -1.22 and a beta of 1.09.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.26. The company had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.12 million. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Ikarian Capital LLC acquired a new stake in Lipocine in the 4th quarter valued at about $1,602,000. Squadron Capital Management LLC acquired a new position in shares of Lipocine in the 4th quarter worth approximately $4,256,000. Boothbay Fund Management LLC bought a new stake in shares of Lipocine in the 4th quarter worth approximately $441,000. Diadema Partners LP bought a new stake in shares of Lipocine in the 4th quarter worth approximately $2,095,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Lipocine during the fourth quarter valued at approximately $567,000. 9.11% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on LPCN shares. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target (up from $7.00) on shares of Lipocine in a research note on Wednesday, January 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.